%PDF-1.4
%
27 0 obj
<>
endobj
24 0 obj
<>
endobj
76 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-08-05T14:36:56Z
2024-03-29T03:07:44-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T03:07:44-07:00
application/pdf
Heather
2004-473.sept
uuid:db773617-1dd1-11b2-0a00-8909277d8900
uuid:db773619-1dd1-11b2-0a00-d30000000000
endstream
endobj
13 0 obj
<>
endobj
14 0 obj
<>
endobj
28 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
86 0 obj
[90 0 R]
endobj
87 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
12 789 587 -785 re
W n
q
0 792.06 612 -792 re
W n
/CS0 CS 0 0 0 1 SCN
/GS1 gs
53.46 77 m
558.47 77 l
S
/CS0 cs 0 0 0 0 scn
52.32 70.16 64.18 -15.66 re
f*
BT
0 0 0 1 scn
/TT0 1 Tf
8 0 0 8 53.3216 57.2343 Tm
(1690)Tj
ET
0 0 0 0 scn
355.5 70.16 203 -15.66 re
f*
BT
0 0 0 1 scn
/TT0 1 Tf
0.02499 Tw 8 0 0 8 423.8613 57.2343 Tm
(The Journal of Rheumatology 2005; 32:9)Tj
/TT1 1 Tf
0.01759 Tw 10 0 0 10 52.968 336.1616 Tm
[(that the prevalence of RA)-212.7 (in our Central European region is)]TJ
0.02499 Tw 0 -1.2 TD
(similar to that found around the world.)Tj
/TT2 1 Tf
-0.00011 Tc 0 Tw 0 -2.4 TD
(REFERENCES)Tj
/TT1 1 Tf
0.02499 Tw 8 0 0 8 59.968 290.1616 Tm
[(1.)-875.1 (MacGregor )54.8 (AJ, Silman )54.8 (AJ. )54.8 (A)-219.9 (reappraisal of the measurement of)]TJ
0 Tc 1.675 -1.25 Td
(disease occurrence in rheumatoid arthritis. J Rheumatol)Tj
0 Tw 0 -1.25 TD
[(1992;19:1)36.9 (163-5.)]TJ
0.0249 Tw -1.675 -1.25 Td
[(2.)-875 (Silman )54.8 (AJ. Rheumatoid arthritis. In: Silman )54.8 (AJ, Hochber)17.8 (g MC, )]TJ
1.675 -1.25 Td
(editors. Epidemiology of the rheumatic diseases. 2nd ed. New)Tj
-0.00011 Tc T*
[(Y)100 (ork: Oxford University Press; 2001:31-71.)]TJ
0 Tc -1.675 -1.25 Td
[(3.)-875 (Gabriel SE. )17.7 (The epidemiology of rheumatoid arthritis. Rheum Dis)]TJ
1.675 -1.25 Td
[(Clin North )54.9 (Am 2001;27:269-81.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(4.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
1.675 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
0 Tc T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24. )]TJ
-0.00011 Tc -1.675 -1.25 Td
[(5.)-875.1 (SPSS Manual. )17.7 (The SPSS Base 7,5 for )17.7 (W)39.7 (indows users guide.)]TJ
1.675 -1.25 Td
[(Chicago, IL: SPSS, 1997. and SPSS for )17.7 (W)39.7 (indows 1)36.8 (1.01, and)]TJ
T*
[(SPSSP)-183.3 (Answer )17.7 (T)34.8 (ree 2.1.1. SPSS Inc. Illinois, USA.)]TJ
-1.675 -1.25 Td
[(6.)-875.1 (Drosos )54.8 (AA, )54.8 (Alamanos I, )17.7 (V)129.1 (oulgari PV)128.8 (, et al. Epidemiology of adult)]TJ
0 Tc 1.675 -1.25 Td
(rheumatoid arthritis in Northwest Greece 1987-1995. J Rheumatol)Tj
0 Tw T*
(1997;26:412-8.)Tj
0.0249 Tw -1.675 -1.25 Td
[(7.)-875 (Riise )17.7 (T)74 (,)0.1 ( Jacobsen BK, Gran JT)74 (. Incidence and prevalence of)]TJ
1.675 -1.25 Td
[(rheumatoid arthritis in the county of )17.7 (T)34.9 (roms, northern Norway)64.9 (. )]TJ
T*
(J Rheumatol 2000;27:1386-9.)Tj
31.325 29.671 Td
[(8.)-875 (Saraux )54.8 (A, Guedes C, )54.8 (Alain J, et al. Prevalence of rheumatoid )]TJ
1.675 -1.25 Td
[(arthritis and spondylarthropathy in Brittany)64.9 (, France. J Rheumatol)]TJ
0 Tw T*
(1999;26:2622-7.)Tj
0.0249 Tw -1.675 -1.25 Td
[(9.)-875 (Carmona L, )17.7 (V)60.1 (illaverde )17.7 (V)129.2 (, Hernandez-Garcia C, Ballina J, Gabriel)]TJ
-0.00011 Tc 1.675 -1.25 Td
[(R, Laf)17.7 (fon )54.8 (A, on behalf of the EPISER Study Group. )17.7 (The )]TJ
0 Tc T*
(prevalence of rheumatoid arthritis in the general population of)Tj
T*
(Spain. Rheumatology 2002;41:88-95.)Tj
-2.175 -1.25 Td
[(10.)-875 (Symmons D, )17.7 (T)34.9 (urner G, )17.7 (W)79.8 (ebb R, et al. )17.7 (The prevalence of )]TJ
2.175 -1.25 Td
(rheumatoid arthritis in the United Kingdom: new estimates for a)Tj
T*
[(new century)64.9 (. Rheumatology 2002;41:793-800.)]TJ
-2.1381 -1.25 Td
[(1)36.9 (1.)-875 (Aho K, Kaipiainen-Seppanen O, Heliovaara M, Klaukka )17.8 (T)74 (.)]TJ
2.1381 -1.25 Td
[(Epidemiology of rheumatoid arthritis in Finland. Semin )54.9 (Arthritis)]TJ
T*
(Rheum 1998;27:325-34.)Tj
-2.175 -1.25 Td
[(12.)-875 (Senna ER, De Barros )54.8 (AL, Silva EO, et al. Prevalence of rheumatic)]TJ
2.175 -1.25 Td
(diseases in Brazil: a study using the COPCORD approach. )Tj
T*
(J Rheumatol 2004;31:594-7.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(13.)-875.1 (Dai SM, Han XH, Zhao DB, Shi )36.7 (YQ, Liu )36.8 (Y)129 (, Meng JM. Prevalence)]TJ
0 Tc 2.175 -1.25 Td
(of rheumatic symptoms, rheumatoid arthritis, ankylosing )Tj
T*
[(spondylitis, and gout in Shanghai, China: a COPCORD study)64.9 (. )]TJ
T*
(J Rheumatol 2003;30:2245-51.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(14.)-875.1 (Gabriel SE, Crowson CS, O\222Fallon )17.7 (WM. )17.7 (The epidemiology of)]TJ
0 Tc 2.175 -1.25 Td
[(rheumatoid arthritis in Rochester)39.8 (, Minnesota, 1955-1985. )54.9 (Arthritis)]TJ
T*
(Rheum 1999;42:415-20.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(15.)-875.1 (MacGregor )54.8 (AJ. Classification criteria for rheumatoid arthritis.)]TJ
0 Tc 2.175 -1.25 Td
(Baillieres Clin Rheumatol 1995;9:287-304.)Tj
ET
Q
Q
q
41.53 743 516.44 -384 re
W* n
q
12 789 587 -785 re
W n
q
0 792.06 612 -792 re
W n
q
/Fm0 Do
Q
Q
Q
Q
q
12 789 587 -785 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.00011 Tc 0.2137 Tw 8 0 0 8 369.032 591.5293 Tm
[(Figur)36.8 (e 1.)]TJ
/TT1 1 Tf
0 Tc 0.21359 Tw 4.3618 0 Td
(Investigation strategy for the identification of)Tj
-0.00011 Tc 0.17281 Tw -4.3618 -1.25 Td
(cases with rheumatoid arthritis. )Tj
0 Tc 0 Tw 6 0 0 6 476.9656 584.1693 Tm
(1)Tj
-0.00011 Tc 0.17281 Tw 8 0 0 8 479.9656 581.5293 Tm
(Number of cases; )Tj
0 Tc 0 Tw 6 0 0 6 542.0833 584.1693 Tm
(2)Tj
-0.00011 Tc 8 0 0 8 545.0833 581.5293 Tm
(sus-)Tj
0 Tc 0.17171 Tw -22.0064 -1.25 Td
[(pected cases who either declared the presence of RA)-366.8 (or)]TJ
0.3607 Tw 0 -1.25 TD
[(mentioned RA)-555.8 (related complaints, or both; )]TJ
0 Tw 6 0 0 6 524.7609 564.1693 Tm
(3)Tj
-0.00011 Tc 8 0 0 8 527.7609 561.5293 Tm
(interview)Tj
0 Tc 0.08501 Tw -19.8411 -1.25 Td
(probands who did not declare any information to indicate)Tj
0.1268 Tw T*
(the presence of RA; )Tj
0 Tw 6 0 0 6 438.8386 544.1693 Tm
(4)Tj
0.1268 Tw 8 0 0 8 441.8386 541.5293 Tm
(individuals who provided informed)Tj
0.25459 Tw -9.1008 -1.25 Td
(consent for a further clinical investigation; )Tj
0 Tw 6 0 0 6 519.4153 534.1693 Tm
(5)Tj
8 0 0 8 522.4153 531.5293 Tm
(individuals)Tj
0.0869 Tw -19.1729 -1.25 Td
(who wanted to remain anonymous; )Tj
0 Tw 6 0 0 6 486.9243 524.1693 Tm
(6)Tj
0.0869 Tw 8 0 0 8 489.9243 521.5293 Tm
(individuals who pro-)Tj
0.0697 Tw -15.1115 -1.25 Td
(vided informed consent for a further clinical investigation)Tj
-0.0009 Tw T*
(of an unrelated arm of the study [these cases came for clin-)Tj
0.159 Tw T*
[(ical investigation due to a disease unrelated to RA)-354.1 (\(pre-)]TJ
0.0881 Tw T*
[(dominantly Raynaud\222)54.9 (s phenomenon\)]; and )]TJ
0 Tw 6 0 0 6 510.4874 484.1693 Tm
(7)Tj
0.0881 Tw 8 0 0 8 513.4874 481.5293 Tm
(individuals in)Tj
-0.00011 Tc 0.202 Tw -18.0569 -1.25 Td
[(whom RA)-397.1 (was confirmed based on )54.9 (ARA)-397.1 (criteria by an)]TJ
0 Tc 0.01421 Tw T*
[(experienced investigator)39.8 (, and further confirmed by another)]TJ
0 Tw T*
(expert.)Tj
ET
0 0 0 0 scn
/GS0 gs
103.13 82.08 407.5 -10.83 re
f*
/CS0 CS 0 0 0 1 SCN
0.5 w
103.13 82.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
11 0 obj
<>stream
HA
1EO;0I&ZA\0E{&%UPؒ*&߃-+SɁ3JuL^x;0|lkòޝog/C7l&%(֍8}` (R
endstream
endobj
10 0 obj
<1.3<>>>
endobj
8 0 obj
<>/ExtGState<>/ProcSet[/PDF/ImageB]/XObject<>>>
endobj
7 0 obj
<>/Filter/CCITTFaxDecode/Height 800/ImageMask true/Length 5165/Subtype/Image/Type/XObject/Width 625>>stream
4p<D|!edFOAn 8E&'O[>RG_4F+:qSy|1
_#>
GA":ȎV#|T(}">`;q?#^
tc>(/_o@`{
ظNWޜX&W|e3GipH#">.ZN[WՏ[_VPմ0_uҽmm#J;d@hdP[\u\d&Bu!9vL<'3'WHre̸iR[Pnw;pC"?)|cxE>?{LW`pDsInV:j=K`hF} ^7ɜgoHh_غ8V.H A}!ſ"WnGizïm.GVQA+F>D~уCPka/MNV9ܘ]C xYpOe)]/u vWa\0dɎS""?-F"g+@2G x arOr q[!JDJ k^6
XD4#sqEpS
GU`'PG8S+j/fm
imEd46a/k!A
l$M i7NIi7Mm]&ԭ#T~zMդA"?z;-N)i?C2/LG~@/~AyhנD~_A~yK7F2<]#ǜ3# *h">\V>aD|n/e7\#GD~GD}GH TG#+pyqe}2ZGD}Aw"?H"!Du
^m{pDoťPHDN"G">P@8{v7Uzq??8/c}z}o_ֿۂbo]E}E8(7qSإD"l
}[j;e>Mkb4
M?}lSXmal쟝bbmM#?
;&;̈_d;V}?A <ȉ_"\5'|⼇|@kWt ']LE>]i9i\kMd4Q#|`F"=G s"?\/r5~7&GF|]r#.AG iDC|˲眈GHNa#k@/#D_ AkycAG'ŏr#ȹ9x,&D}.@Z#|wbG@GGޖ"=7ނ7pAb#"D~ Рk
#E?[C{7GۂfB"#(}~Q^_~4Udukv%i#|m͋cPp°ak^]S
qe!{U_w}_߿ YK|*_t ߿xO_i/G;57Dt+U@kx7觱[@Gհ|kkЇ__mKKc &2_'q`B"?Zf/__ޯzkZ].J6+iZ+l%m[
I
A%m&L0Ml9Ka`"0dp<4<`p<TJ x;b"0dܝnwLuPm/?-988o_ |jc"3q3<5 ex4<
$GE:5"[[ GeyD(ؘh0006
AMÄm&al H6*I+6m[I:]2One vZD#D27MF5#H"?+[`#Dxԫ)/?_5*&.D~a"`Hh봂#[g)o@;D}//z
+c>_|oG@duoq+zz}wUإ>l_i4hS&UhVS4e:iR;4\kk?R"&5R"'x'ιd5k_'Α̉dnkC^>**?qw!IL/#EѴaJ_0V]e˹r>_#x.˴r#|'"<]c A^_H/3v]2^.2>_#|.^IZA-hE@#zG G}<_z#~
݂#_o#Gxפ-Qck8&"?cpM"?_V_P GAo(uzh}ݠW~!)@!#cX}lݨt2XGŲ<"?*>v-ƹP_u_u}_;=UY]}_}WQE[_E]L:W_@x"?k_]_pD{$K_O$H"t2<mWФV
?_==uu}WIմw=6mm]-i6+jt6i6g*a 0VM +$a``f|C v6a b" v'2#r1r
b" ̂*C (feG߭_;R8fs\B _79ٗ*rOKQ.r/;+Q
3q16uPDpV6pړAMAm 7IJ~6OKzҿڿwR3Iy=Ng2+d>d8]Hȏﶦw5Etʚۍib#zs3Gg_gv]4/q]˷"=>";.˲{#>#r #D}?@uE X"? #DyD}#h">"Io#Hl$B}_`=}Sq\KL{("}?;B{E[qkMZUEF]#W{*;h">ފyu[[ N)E?ߒ鿽oKaŠ}A.5cOCPGHE⿓qQ\TE&!&_AʅgiDq"3~?/3gIj+85_IewWk^W^GK_^#D|Ћ믾_Wuuzzڷ[Jm+ki:[II0M`af2:#6Lܬ4t@W[2ۊ1E~
endstream
endobj
60 0 obj
<>
endobj
35 0 obj
[/ICCBased 62 0 R]
endobj
62 0 obj
<>stream
H앉_ǟESIBtJd))v%Ii9E#rN{N("$4$&4ݐ62u6 ]<'f̌l>w@Vr@X?~J;?tƃ
H", !!p~]9)Zk?YZ3\e}AJ לkKHr@2ל
~|x~[ #yƵ6?0ll6ocllĶdD#ٶ!<Xk#x=/),7?\l1v-r6$JiI5I[0h\Ll5tJ*g~u={v̸PsѶEW_..vfQw[Ы;]}'N.J_/e_w7ަ?]LUL\OAbD1aR %֒|lϸq28r宏?$Rb*p+%O>^I*J*,q&b9jZ4iϧk7=د4r43"jg|5P\9sӜwe~u:^9J~
_oalbtq&&uK6MoWXHZ4ZYX=.[kjӽLVsEJw)vBujwXʸvx~5kgj.Xcʯۿ'
z70gƖMsxZkF(ED>ojv%!1im;v
^K$5tڧys$#C:L5+7z_oDT/pBxsIǑ%e>+ﭰ?yUgktkkꖜ8|AކM+-sZͮ{wnsw̝~}#'kּ;ő7oS>s?@ω/+T6z*5QIT$-o>%A@+<2N 5QDo&2\d